Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisavanbulin SCHEMBL18466601 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| Lisavanbulin SCHEMBL29374059 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| Lisavanbulin SCHEMBL30370051 | 0.99 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL15472848 | 0.93 | SMN1; SMN2 (0.45) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL17826524 | 0.93 | SMN1; SMN2 (0.48) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL11890482 | 0.93 | SMN1; SMN2 (0.48) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL18466603 | 0.93 | SMN1; SMN2 (0.48) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL13449690 | 0.92 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL15441152 | 0.91 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 | |
| SCHEMBL15942979 | 0.91 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-108139405-B | Use of EB1 as a biomarker of drug response | 巴斯利尔药物国际股份公司 | 2022-06-10 | — | — | CN | claimed |
| WO-2022053549-A1 | USE OF C-MYC AS A BIOMARKER OF DRUG RESPONSE | Basilea Pharmaceutica International AG (CH) | 2022-03-17 | — | — | WO | claimed |
| EP-4733415-A1 | A METHOD OF RISK STRATIFICATION FOR LOW RISK PROSTATE CANCER PATIENTS | Koninklijke Philips N.V. (NL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20140080872-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-20140045897-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045897-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140024686-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-20140024686-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| WO-2011012577-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012577-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | SSB, VHL, AHR | ALDH1A1 838/4885HSD17B10 701/4885KDM4E 926/4885 |
| US-20140024686-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | TUBB, TUBB1, TUBB6 | ALDH1A1 1153/4885HSD17B10 2199/4885KDM4E 4206/4885 |
| US-20140045897-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BUB1B, BUB1, BUB3 | ALDH1A1 1640/4885HSD17B10 1484/4885KDM4E 2211/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ALDH1A1 115/4885HSD17B10 2402/4885KDM4E 1134/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ALDH1A1 4095/4885HSD17B10 1854/4885KDM4E 1748/4885 |
| US-20140080872-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | ALDH1A1 4641/4885HSD17B10 1677/4885KDM4E 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.